Clinical Research Directory
Browse clinical research sites, groups, and studies.
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Sponsor: Massachusetts General Hospital
Summary
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.
Official title: Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2868
Start Date
2018-02-16
Completion Date
2028-07-01
Last Updated
2025-10-03
Healthy Volunteers
No
Conditions
Interventions
Aspirin 325mg
Aspirin 325 mg by mouth once daily
Enoxaparin 40Mg/0.4mL Prefilled Syringe
Enoxaparin 40 mg subcutaneous injection once daily
Locations (10)
University of California Los Angeles Health
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Louisiana State University Health
New Orleans, Louisiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Santiago Lozano-Calderon
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Missouri-Columbia Cancer Care
Columbia, Missouri, United States
Cooper University Health Care
Camden, New Jersey, United States
Cleveland Clinic
Cleveland, Ohio, United States